{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:48:07Z","timestamp":1788403687053,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360505"],"award-info":[{"award-number":["82360505"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360545"],"award-info":[{"award-number":["82360545"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010857","name":"Jiangxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["20213BCJL22048"],"award-info":[{"award-number":["20213BCJL22048"]}],"id":[{"id":"10.13039\/501100010857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02498-0","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T07:38:20Z","timestamp":1762414700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeting SHP2 to reverse immune evasion and resistance to anti-PD-1 therapy in non-small cell lung cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Shiwei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingguo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongbing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"2498_CR1","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/JCO.2012.46.9270","volume":"31","author":"WD Travis","year":"2013","unstructured":"Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31:992\u20131001.","journal-title":"J Clin Oncol"},{"key":"2498_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2498_CR3","doi-asserted-by":"publisher","first-page":"13534","DOI":"10.1021\/acs.jmedchem.4c00360","volume":"67","author":"C Ma","year":"2024","unstructured":"Ma C, Kang D, Gao P, Zhang W, Wu X, Xu Z, et al. Discovery of JAB-3312, a potent SHP2 allosteric inhibitor for cancer treatment. J Med Chem. 2024;67:13534\u201349.","journal-title":"J Med Chem"},{"key":"2498_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2022;40:586\u201397.","journal-title":"J Clin Oncol"},{"key":"2498_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.1285","volume":"7","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Li A, Yu H, Wang Y, Zhang X, Qiu H, et al. Neoadjuvant-adjuvant vs neoadjuvant-only PD-1 and PD-L1 inhibitors for patients with resectable NSCLC: an indirect meta-analysis. JAMA Netw Open. 2024;7:e241285.","journal-title":"JAMA Netw Open"},{"key":"2498_CR6","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","volume":"56","author":"JR Giles","year":"2023","unstructured":"Giles JR, Globig AM, Kaech SM, Wherry EJ. CD8(+) T cells in the cancer-immunity cycle. Immunity. 2023;56:2231\u201353.","journal-title":"Immunity"},{"key":"2498_CR7","doi-asserted-by":"crossref","unstructured":"S. Kumagai, S. Koyama, K. Itahashi, T. Tanegashima, Y.T. Lin, Y. Togashi, T. Kamada, T. Irie, G. Okumura, H. Kono, D. Ito, R. Fujii, S. Watanabe, A. Sai, S. Fukuoka, E. Sugiyama, G. Watanabe, T. Owari, H. Nishinakamura, D. Sugiyama, Y. Maeda, A. Kawazoe, H. Yukami, K. Chida, Y. Ohara, T. Yoshida, Y. Shinno, Y. Takeyasu, M. Shirasawa, K. Nakama, K. Aokage, J. Suzuki, G. Ishii, T. Kuwata, N. Sakamoto, M. Kawazu, T. Ueno, T. Mori, N. Yamazaki, M. Tsuboi, Y. Yatabe, T. Kinoshita, T. Doi, K. Shitara, H. Mano, H. Nishikawa, Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments, Cancer Cell. 2022;40:201\u2013218 e209.","DOI":"10.1016\/j.ccell.2022.01.001"},{"key":"2498_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41416-022-01960-x","volume":"128","author":"K Abiko","year":"2023","unstructured":"Abiko K, Hamanishi J, Matsumura N, Mandai M. Dynamic host immunity and PD-L1\/PD-1 blockade efficacy: developments after \u201cIFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.\u201d Br J Cancer. 2023;128:461\u20137.","journal-title":"Br J Cancer"},{"key":"2498_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-gamma in tumor progression and regression: a review. Biomark Res. 2020;8:49.","journal-title":"Biomark Res"},{"key":"2498_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature09907","volume":"472","author":"JW Schoggins","year":"2011","unstructured":"Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472:481\u20135.","journal-title":"Nature"},{"key":"2498_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101512","volume":"5","author":"Y Yang","year":"2024","unstructured":"Yang Y, Wang Y, Zeng F, Chen Y, Chen Z, Yan F. Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy. Cell Rep Med. 2024;5:101512.","journal-title":"Cell Rep Med"},{"key":"2498_CR12","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.cmet.2024.01.005","volume":"36","author":"C Hu","year":"2024","unstructured":"Hu C, Qiao W, Li X, Ning ZK, Liu J, Dalangood S, et al. Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8(+)T cells. Cell Metab. 2024;36:630-647 e638.","journal-title":"Cell Metab"},{"key":"2498_CR13","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41568-023-00615-0","volume":"23","author":"T Gebhardt","year":"2023","unstructured":"Gebhardt T, Park SL, Parish IA. Stem-like exhausted and memory CD8(+) T cells in cancer. Nat Rev Cancer. 2023;23:780\u201398.","journal-title":"Nat Rev Cancer"},{"key":"2498_CR14","doi-asserted-by":"crossref","unstructured":"A. Chow, F.Z. Uddin, M. Liu, A. Dobrin, B.Y. Nabet, L. Mangarin, Y. Lavin, H. Rizvi, S.E. Tischfield, A. Quintanal-Villalonga, J.M. Chan, N. Shah, V. Allaj, P. Manoj, M. Mattar, M. Meneses, R. Landau, M. Ward, A. Kulick, C. Kwong, M. Wierzbicki, J. Yavner, J. Egger, S.S. Chavan, A. Farillas, A. Holland, H. Sridhar, M. Ciampricotti, D. Hirschhorn, X. Guan, A.L. Richards, G. Heller, J. Mansilla-Soto, M. Sadelain, C.A. Klebanoff, M.D. Hellmann, T. Sen, E. de Stanchina, J.D. Wolchok, T. Merghoub, C.M. Rudin, The ectonucleotidase CD39 identifies tumor-reactive CD8(+) T cells predictive of immune checkpoint blockade efficacy in human lung cancer, Immunity. 2023;56:93\u2013106 e106.","DOI":"10.1016\/j.immuni.2022.12.001"},{"key":"2498_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.tem.2014.10.004","volume":"26","author":"EN Gurzov","year":"2015","unstructured":"Gurzov EN, Stanley WJ, Brodnicki TC, Thomas HE. Protein tyrosine phosphatases: molecular switches in metabolism and diabetes. Trends Endocrinol Metab. 2015;26:30\u20139.","journal-title":"Trends Endocrinol Metab"},{"key":"2498_CR16","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12935-020-01315-7","volume":"20","author":"J Chen","year":"2020","unstructured":"Chen J, Zhao X, Yuan Y, Jing JJ. The expression patterns and the diagnostic\/prognostic roles of PTPN family members in digestive tract cancers. Cancer Cell Int. 2020;20:238.","journal-title":"Cancer Cell Int"},{"key":"2498_CR17","doi-asserted-by":"crossref","unstructured":"Y. Pan, H. Han, H. Hu, H. Wang, Y. Song, Y. Hao, X. Tong, A.S. Patel, S. Misirlioglu, S. Tang, H.Y. Huang, K. Geng, T. Chen, A. Karatza, F. Sherman, K.E. Labbe, F. Yang, A. Chafitz, C. Peng, C. Guo, A.L. Moreira, V. Velcheti, S.C.M. Lau, P. Sui, H. Chen, J.A. Diehl, A.K. Rustgi, A.J. Bass, J.T. Poirier, X. Zhang, H. Ji, H. Zhang, K.K. Wong, KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition, Cancer Cell. 2023;41:88\u2013105 e108.","DOI":"10.1016\/j.ccell.2022.11.015"},{"key":"2498_CR18","doi-asserted-by":"crossref","unstructured":"P. Anastasiou, C. Moore, S. Rana, M. Tomaschko, C.E. Pillsbury, A. de Castro, J. Boumelha, E. Mugarza, S. de Carne Trecesson, A. Mikolajczak, C. Blaj, R. Goldstone, J.A.M. Smith, E. Quintana, M. Molina-Arcas, J. Downward, Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade, Nat Commun. 2024;15:8146.","DOI":"10.1038\/s41467-024-52324-3"},{"key":"2498_CR19","doi-asserted-by":"crossref","unstructured":"G. Zhu, J. Xie, W. Kong, J. Xie, Y. Li, L. Du, Q. Zheng, L. Sun, M. Guan, H. Li, T. Zhu, H. He, Z. Liu, X. Xia, C. Kan, Y. Tao, H.C. Shen, D. Li, S. Wang, Y. Yu, Z.H. Yu, Z.Y. Zhang, C. Liu, J. Zhu, Phase Separation of Disease-Associated SHP2 Mutants Underlies MAPK Hyperactivation, Cell. 2020;183:490\u2013502 e418.","DOI":"10.1016\/j.cell.2020.09.002"},{"key":"2498_CR20","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.jaci.2022.06.021","volume":"150","author":"N Panchal","year":"2022","unstructured":"Panchal N, Houghton BC, Vassalou E, Thrasher AJ, Booth C. Allosteric inhibition of SHP2 rescues functional T-cell abnormalities in SAP deficiency. J Allergy Clin Immunol. 2022;150:1507-1516 e1507.","journal-title":"J Allergy Clin Immunol"},{"key":"2498_CR21","doi-asserted-by":"publisher","first-page":"9155","DOI":"10.1039\/D3CP03923D","volume":"26","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Ouyang W, Liu L, Tang L, Zhang Z, Yue X, et al. Molecular recognition of ITIM\/ITSM domains with SHP2 and their allosteric effect. Phys Chem Chem Phys. 2024;26:9155\u201369.","journal-title":"Phys Chem Chem Phys"},{"key":"2498_CR22","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","volume":"355","author":"E Hui","year":"2017","unstructured":"Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355:1428\u201333.","journal-title":"Science"},{"key":"2498_CR23","doi-asserted-by":"crossref","unstructured":"B. Wang, W. Zhang, V. Jankovic, J. Golubov, P. Poon, E.M. Oswald, C. Gurer, J. Wei, I. Ramos, Q. Wu, J. Waite, M. Ni, C. Adler, Y. Wei, L. Macdonald, T. Rowlands, S. Brydges, J. Siao, W. Poueymirou, D. MacDonald, G.D. Yancopoulos, M.A. Sleeman, A.J. Murphy, D. Skokos, Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8(+) T cell dysfunction and maintain memory phenotype. Sci Immunol. 2018;3(29):eaat7061.","DOI":"10.1126\/sciimmunol.aat7061"},{"key":"2498_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nature18621","volume":"535","author":"YN Chen","year":"2016","unstructured":"Chen YN, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG, et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature. 2016;535:148\u201352.","journal-title":"Nature"},{"key":"2498_CR25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2318773121","volume":"121","author":"A S. Melique","year":"2024","unstructured":"S. Melique A, A. Vadel A, N. Rouquie A, C. Yang A, C. Bories A, C. Cotineau A, et al. THEMIS promotes T cell development and maintenance by rising the signaling threshold of the inhibitory receptor BTLA. Proc Natl Acad Sci U S A. 2024;121:e2318773121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2498_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12943-021-01448-x","volume":"20","author":"SW Chen","year":"2021","unstructured":"Chen SW, Zhu SQ, Pei X, Qiu BQ, Xiong D, Long X, et al. Cancer cell-derived exosomal circUSP7 induces CD8(+) T cell dysfunction and anti-PD1 resistance by regulating the miR-934\/SHP2 axis in NSCLC. Mol Cancer. 2021;20:144.","journal-title":"Mol Cancer"},{"key":"2498_CR27","doi-asserted-by":"crossref","unstructured":"A. Deya-Martinez, J.G. Riviere, P. Roxo-Junior, J. Ramakers, M. Bloomfield, P. Guisado Hernandez, P. Blanco Lobo, S.R. Abu Jamra, A. Esteve-Sole, V. Kanderova, A. Garcia-Garcia, M. Lopez-Corbeto, N. Martinez Pomar, A. Martin-Nalda, L. Alsina, O. Neth, P. Olbrich, Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations-10 Children and Review of the Literature, J Clin Immunol.2022;42:1071\u20131082.","DOI":"10.1007\/s10875-022-01257-x"},{"key":"2498_CR28","doi-asserted-by":"publisher","first-page":"e112259","DOI":"10.15252\/embj.2022112259","volume":"42","author":"SS Tehrani","year":"2023","unstructured":"Tehrani SS, Mikulski P, Abdul-Zani I, Mata JF, Siwek W, Jansen LE. STAT1 is required to establish but not maintain interferon-gamma-induced transcriptional memory. EMBO J. 2023;42:e112259.","journal-title":"EMBO J"},{"key":"2498_CR29","doi-asserted-by":"publisher","first-page":"eadk2612","DOI":"10.1126\/sciimmunol.adk2612","volume":"9","author":"R Zhao","year":"2024","unstructured":"Zhao R, Zhang J, Ma J, Qu Y, Yang Z, Yin Z, et al. cGAS-activated endothelial cell-T cell cross-talk initiates tertiary lymphoid structure formation. Sci Immunol. 2024;9:eadk2612.","journal-title":"Sci Immunol"},{"key":"2498_CR30","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/0008-5472.CAN-23-0902","volume":"84","author":"C Jacobs","year":"2024","unstructured":"Jacobs C, Shah S, Lu WC, Ray H, Wang J, Hockaden N, et al. HSF1 inhibits antitumor immune activity in breast cancer by suppressing CCL5 to block CD8+ T-cell recruitment. Cancer Res. 2024;84:276\u201390.","journal-title":"Cancer Res"},{"key":"2498_CR31","doi-asserted-by":"crossref","unstructured":"D. Dangaj, M. Bruand, A.J. Grimm, C. Ronet, D. Barras, P.A. Duttagupta, E. Lanitis, J. Duraiswamy, J.L. Tanyi, F. Benencia, J. Conejo-Garcia, H.R. Ramay, K.T. Montone, D.J. Powell, Jr., P.A. Gimotty, A. Facciabene, D.G. Jackson, J.S. Weber, S.J. Rodig, S.F. Hodi, L.E. Kandalaft, M. Irving, L. Zhang, P. Foukas, S. Rusakiewicz, M. Delorenzi, G. Coukos, Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors, Cancer Cell.2019;35:885\u2013900 e810.","DOI":"10.1016\/j.ccell.2019.05.004"},{"key":"2498_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13073-023-01164-9","volume":"15","author":"J Hu","year":"2023","unstructured":"Hu J, Zhang L, Xia H, Yan Y, Zhu X, Sun F, et al. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Med. 2023;15:14.","journal-title":"Genome Med"},{"key":"2498_CR33","doi-asserted-by":"crossref","unstructured":"C.J. Liu, F.F. Hu, G.Y. Xie, Y.R. Miao, X.W. Li, Y. Zeng, A.Y. Guo, GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels. Brief Bioinform. 2023;24(1):bbac558.","DOI":"10.1093\/bib\/bbac558"},{"key":"2498_CR34","doi-asserted-by":"crossref","unstructured":"Fedele, S. Li, K.W. Teng, C.J.R. Foster, D. Peng, H. Ran, P. Mita, M.J. Geer, T. Hattori, A. Koide, Y. Wang, K.H. Tang, J. Leinwand, W. Wang, B. Diskin, J. Deng, T. Chen, I. Dolgalev, U. Ozerdem, G. Miller, S. Koide, K.K. Wong, B.G. Neel, SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. J Exp Med. 2021;218(1):e20201414.","DOI":"10.1084\/jem.20201414"},{"key":"2498_CR35","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1073\/pnas.1309342111","volume":"111","author":"J Heuberger","year":"2014","unstructured":"Heuberger J, Kosel F, Qi J, Grossmann KS, Rajewsky K, Birchmeier W. Shp2\/MAPK signaling controls goblet\/paneth cell fate decisions in the intestine. Proc Natl Acad Sci U S A. 2014;111:3472\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2498_CR36","first-page":"43","volume":"4","author":"J Qiu","year":"2023","unstructured":"Qiu J, Xu B, Ye D, Ren D, Wang S, Benci JL, et al. Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction. Nat Cancer. 2023;4:43\u201361.","journal-title":"Nat Cancer"},{"key":"2498_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215712","volume":"539","author":"PC Tseng","year":"2022","unstructured":"Tseng PC, Chen CL, Lee KY, Feng PH, Wang YC, Satria RD, et al. Epithelial-to-mesenchymal transition hinders interferon-gamma-dependent immunosurveillance in lung cancer cells. Cancer Lett. 2022;539:215712.","journal-title":"Cancer Lett"},{"key":"2498_CR38","doi-asserted-by":"publisher","first-page":"5088","DOI":"10.1038\/s41388-018-0337-6","volume":"37","author":"P Xiao","year":"2018","unstructured":"Xiao P, Guo Y, Zhang H, Zhang X, Cheng H, Cao Q, et al. Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-gamma production in tumor microenvironment. Oncogene. 2018;37:5088\u2013100.","journal-title":"Oncogene"},{"key":"2498_CR39","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/ijc.31357","volume":"143","author":"Y Gao","year":"2018","unstructured":"Gao Y, Yang J, Cai Y, Fu S, Zhang N, Fu X, et al. IFN-gamma-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. Int J Cancer. 2018;143:931\u201343.","journal-title":"Int J Cancer"},{"key":"2498_CR40","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12943-023-01900-0","volume":"22","author":"P Knopf","year":"2023","unstructured":"Knopf P, Stowbur D, Hoffmann SHL, Hermann N, Maurer A, Bucher V, et al. Acidosis-mediated increase in IFN-gamma-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors. Mol Cancer. 2023;22:207.","journal-title":"Mol Cancer"},{"key":"2498_CR41","doi-asserted-by":"crossref","first-page":"1032\u20131050 e1010","DOI":"10.1016\/j.ccell.2024.04.011","volume":"42","author":"MJ van Elsas","year":"2024","unstructured":"van Elsas MJ, Middelburg J, Labrie C, Roelands J, Schaap G, Sluijter M, et al. Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell. 2024;42:1032-1050 e1010.","journal-title":"Cancer Cell."},{"key":"2498_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109438","volume":"36","author":"IH Seo","year":"2021","unstructured":"Seo IH, Eun HS, Kim JK, Lee H, Jeong S, Choi SJ, et al. IL-15 enhances CCR5-mediated migration of memory CD8(+) T cells by upregulating CCR5 expression in the absence of TCR stimulation. Cell Rep. 2021;36:109438.","journal-title":"Cell Rep"},{"key":"2498_CR43","doi-asserted-by":"crossref","unstructured":"A. Pant, B. Hwa-Lin Bergsneider, S. Srivastava, T. Kim, A. Jain, S. Bom, P. Shah, N. Kannapadi, K. Patel, J. Choi, K.B. Cho, R. Verma, C. Yu-Ju Wu, H. Brem, B. Tyler, D.M. Pardoll, C. Jackson, M. Lim, CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy, Oncoimmunology. 2024;13:2338965.","DOI":"10.1080\/2162402X.2024.2338965"},{"key":"2498_CR44","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.1158\/0008-5472.CAN-11-1687","volume":"71","author":"A Gonzalez-Martin","year":"2011","unstructured":"Gonzalez-Martin A, Gomez L, Lustgarten J, Mira E, Manes S. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res. 2011;71:5455\u201366.","journal-title":"Cancer Res"},{"key":"2498_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000624","volume":"5","author":"D Kotani","year":"2020","unstructured":"Kotani D, Bando H, Taniguchi H, Masuishi T, Komatsu Y, Yamaguchi K, Nakajima T, Satoh T, Nishina T, Esaki T, Nomura S, Takahashi K, Iida S, Matsuda S, Motonaga S, Fuse N, Sato A, Fujii S, Ohtsu A, Ebi H, Yoshino T, BIG BANG study. Big bang study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer. ESMO Open. 2020;5: e000624 (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer.","journal-title":"ESMO Open"},{"key":"2498_CR46","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.20.02088","volume":"39","author":"J Tabernero","year":"2021","unstructured":"Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol. 2021;39:273\u201384.","journal-title":"J Clin Oncol"},{"key":"2498_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay4458","volume":"6","author":"M Marasco","year":"2020","unstructured":"Marasco M, Berteotti A, Weyershaeuser J, Thorausch N, Sikorska J, Krausze J, et al. Molecular mechanism of SHP2 activation by PD-1 stimulation. Sci Adv. 2020;6:eaay4458.","journal-title":"Sci Adv"},{"key":"2498_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102020","volume":"6","author":"D Zheng","year":"2025","unstructured":"Zheng D, Qin L, Lv J, Che M, He B, Zheng Y, et al. CD4(+) anti-TGF-beta CAR T cells and CD8(+) conventional CAR T cells exhibit synergistic antitumor effects. Cell Rep Med. 2025;6:102020.","journal-title":"Cell Rep Med"},{"key":"2498_CR49","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.celrep.2018.03.026","volume":"23","author":"G Rota","year":"2018","unstructured":"Rota G, Niogret C, Dang AT, Barros CR, Fonta NP, Alfei F, et al. Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo. Cell Rep. 2018;23:39\u201349.","journal-title":"Cell Rep"},{"key":"2498_CR50","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2025.1002297","volume":"6","author":"L Cabezon-Gutierrez","year":"2025","unstructured":"Cabezon-Gutierrez L, Palka-Kotlowska M, Custodio-Cabello S, Chacon-Ovejero B, Pacheco-Barcia V. Metabolic mechanisms of immunotherapy resistance. Explor Target Antitumor Ther. 2025;6:1002297.","journal-title":"Explor Target Antitumor Ther"},{"key":"2498_CR51","doi-asserted-by":"publisher","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","volume":"77","author":"GC Prendergast","year":"2017","unstructured":"Prendergast GC, Malachowski WP, DuHadaway JB, Muller AJ. Discovery of IDO1 inhibitors: from bench to bedside. Cancer Res. 2017;77:6795\u2013811.","journal-title":"Cancer Res"},{"key":"2498_CR52","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/2159-8290.CD-18-0444","volume":"8","author":"C Fedele","year":"2018","unstructured":"Fedele C, Ran H, Diskin B, Wei W, Jen J, Geer MJ, et al. Shp2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models. Cancer Discov. 2018;8:1237\u201349.","journal-title":"Cancer Discov"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02498-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02498-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02498-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:06:27Z","timestamp":1762416387000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-025-02498-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2498"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02498-0","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethical approval was provided by the Ethics Committee of the Second Affiliated Hospital of Nanchang University, and written informed consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"478"}}